Best Peptides for Weight Loss for Women: AOD-9604, GLP-1, and More

Weight loss for women is biologically distinct from weight loss for men — and the peptide interventions that work best reflect those differences. Women have higher baseline body fat percentages, different fat distribution patterns (subcutaneous vs. visceral), greater hormonal variability across the cycle and life stages, and different metabolic responses to energy restriction.

This guide covers the most evidence-supported peptides for fat loss in women, how they compare to GLP-1 medications like semaglutide, and how to think about combining these tools strategically.

Why Women's Fat Loss Biology Differs

Several physiological factors shape how women respond to fat loss interventions:

• Estrogen promotes subcutaneous fat storage (hips, thighs) as an evolutionary reproductive reserve — this fat is more resistant to lipolysis than visceral fat
• Women have more lipoprotein lipase activity in subcutaneous fat depots, making them biologically inclined to store fat in those areas
• Caloric restriction triggers stronger adaptive metabolic responses in women, including greater drops in thyroid hormone and leptin, which is why crash dieting tends to backfire more severely in women
• Hormonal fluctuations across the menstrual cycle affect appetite, fluid retention, and energy expenditure by up to 200–300 calories per day

Effective peptide interventions work with these biological patterns rather than against them.

AOD-9604: The Fat-Specific Fragment

AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone (amino acids 176–191). It was specifically engineered to retain GH's lipolytic properties while eliminating its effects on blood glucose and IGF-1 — the parts that cause the side effects of exogenous GH.

How It Works

AOD-9604 stimulates the breakdown of stored fat (lipolysis) and inhibits new fat formation (lipogenesis) through mechanisms that appear to involve beta-3 adrenergic receptors. Unlike full GH, it does not cause insulin resistance, does not raise IGF-1 (so no cancer-promotion concerns), and does not affect blood glucose.

It has shown particular activity on visceral and abdominal fat — the metabolically active fat associated with cardiovascular and metabolic disease risk.

Research Evidence

AOD-9604 completed Phase IIb and Phase III clinical trials for obesity in Australia and received GRAS (generally regarded as safe) status from the FDA for use as a food ingredient — giving it one of the better safety records of any fat-loss peptide.

Phase II trials showed statistically significant weight loss compared to placebo over 12 weeks, with particular reduction in abdominal fat. However, Phase III results were more modest, which is why it never achieved pharmaceutical approval as a stand-alone obesity drug.

For women, AOD-9604's abdominal fat targeting is particularly relevant because visceral adiposity is a key driver of metabolic disease risk even in women with predominantly subcutaneous fat distribution.

Dosing

300 mcg subcutaneously, before breakfast (fasted), daily. Some protocols use intranasal administration. Cycle length is typically 3–6 months.

CJC-1295 / Ipamorelin: Recomposition Through GH Optimization

The CJC-1295 and ipamorelin combination approaches fat loss indirectly through GH optimization — and for many women, this is the most sustainable and health-promoting approach.

Why It Works for Women's Weight Loss

Growth hormone is a potent lipolytic hormone. It mobilizes free fatty acids from adipose tissue for energy, preferentially targeting visceral fat. In women over 35, declining GH output is a major contributor to the body composition changes — more fat, less muscle — that make weight maintenance increasingly difficult.

By restoring GH pulsatility to levels more consistent with a younger physiology, CJC-1295/ipamorelin produces:

• Preferential reduction in visceral and abdominal fat
• Preservation or improvement of lean mass (avoiding the muscle loss that accompanies most caloric restriction diets)
• Improved sleep quality, which reduces cortisol and the fat-storing effects of sleep deprivation
• Better insulin sensitivity over time

What to Expect

This is not a rapid fat loss approach. Over 3–6 months of consistent use, women typically see a 5–15% reduction in body fat percentage, with the greatest changes in visceral fat and improved muscle tone. Combined with appropriate training and nutrition, results are considerably better.

Dosing

CJC-1295 (no DAC): 100–200 mcg + Ipamorelin: 100–200 mcg subcutaneously before bed. Note that women often see strong effects at the lower end of these ranges due to greater baseline GH sensitivity.

Tesamorelin: Visceral Fat Reduction with Clinical Evidence

Tesamorelin is an FDA-approved GHRH analog (approved under the name Egrifta) for the reduction of visceral adiposity in HIV patients. It is perhaps the most clinically validated peptide for abdominal fat loss and is increasingly used off-label in general wellness and body composition contexts.

How It Works

Tesamorelin binds to pituitary GHRH receptors and stimulates GH release in pulses, producing approximately a 2-fold increase in IGF-1 over baseline. Unlike continuous GH administration, pulsatile delivery maintains insulin sensitivity and avoids many of the side effects of exogenous HGH.

Research Evidence

Multiple randomized controlled trials in HIV-positive patients with lipodystrophy demonstrate significant visceral fat reduction — up to 15–18% over 26 weeks — compared to placebo. Studies in non-HIV populations also show meaningful abdominal fat reduction, improved lipid profiles, and metabolic benefits.

For women with significant visceral adiposity or metabolic syndrome features, tesamorelin represents one of the most evidence-backed options available.

Dosing

2 mg subcutaneously, once daily, before bed or in the morning fasted. Cycles of 3–6 months are typical, with IGF-1 monitoring. Available by prescription through some compounding pharmacies.

Semaglutide Comparison: What GLP-1 Medications Do That Peptides Don't

Semaglutide (Ozempic/Wegovy) has dominated the weight loss conversation since 2021, and for good reason — clinical trials show 12–15% average body weight reduction over 68 weeks, the largest effect size of any approved weight loss medication in history.

Understanding where semaglutide fits relative to the peptides above helps clarify the decision:

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist. GLP-1 is an incretin hormone released by the gut after eating. Semaglutide mimics this signal continuously, reducing appetite, slowing gastric emptying, improving insulin secretion, and through CNS GLP-1 receptor activation, reducing the reward value of food.

For a deeper look at GLP-1 peptides, see the GLP-1 peptides guide.

Semaglutide vs. AOD-9604 / Tesamorelin

| Factor | Semaglutide | AOD-9604 / Tesamorelin | |---|---|---| | Weight loss magnitude | Very high (12–15%) | Moderate (5–10%) | | Mechanism | Appetite suppression + GLP-1 signaling | GH-mediated lipolysis | | Muscle mass | May reduce lean mass | Preserves/improves lean mass | | Insulin sensitivity | Improves significantly | Neutral to slightly improved | | Side effects | Nausea, vomiting (common), rare but serious | Generally mild | | Availability | Prescription only | Research or prescription |

The key distinction: GLP-1 drugs primarily reduce caloric intake (appetite suppression). GH-optimizing peptides primarily improve fat metabolism and body composition without necessarily creating a large caloric deficit. For women focused on recomposition — losing fat while maintaining or building lean mass — GH-based peptides are often superior even with smaller total weight loss numbers.

Many physicians now combine low-dose semaglutide with GH secretagogues to get the appetite benefits of GLP-1 while preserving lean mass through GH optimization.

Stacking for Women's Fat Loss

A practical combined approach:

• Foundation: CJC-1295/ipamorelin before bed — addresses GH decline, preserves lean mass, improves sleep and recovery
• Targeted fat loss: AOD-9604 fasted in the morning — adds direct lipolytic activity
• Optional: Low-dose semaglutide (0.25–0.5 mg/week) for appetite regulation if caloric adherence is the primary challenge

For more stacking strategies, see the best peptide stacks guide.

Frequently Asked Questions

Q: Is AOD-9604 safe for long-term use in women? AOD-9604 has an FDA GRAS designation and completed Phase III trials without significant safety signals. Long-term human data beyond 1–2 years is limited, so conservative cycling (3–6 months on, 1–2 months off) is the standard approach.

Q: Will peptides help with menopausal weight gain? Yes, particularly GH secretagogues. Menopausal weight gain is partly driven by declining GH and estrogen, which together accelerate visceral fat accumulation. Tesamorelin and CJC-1295/ipamorelin directly address the GH component.

Q: Can I use these peptides while doing intermittent fasting? AOD-9604 is typically taken fasted in the morning, which is compatible with IF protocols. GH secretagogues work best before bed, which is unaffected by IF timing. The combination of IF and GH optimization can produce synergistic fat loss effects.

Q: How do peptides for fat loss differ from diet pills? Diet pills typically work through appetite suppression (stimulants, GLP-1 drugs) or fat absorption inhibition. Peptides like AOD-9604 and tesamorelin work through metabolic mechanisms — improving how the body handles and burns fat — rather than simply reducing intake. This makes them more complementary to a healthy lifestyle than replacements for one.

Q: Do I need to follow a specific diet with these peptides? Peptides are not magic — they work best when paired with appropriate nutrition. Specifically, GH secretagogues are most effective when carbohydrate intake around the nighttime injection is low (GH release is blunted by insulin). AOD-9604 fasted in the morning is similarly best with no food or caloric beverages in the preceding 2–3 hours.